TSLA
PLTR
HIMS
SPCX
SOFI
BTCValuation snapshot, analyst consensus, international business and Q1 preview
Analyst consensus
- Average price target
$31.71
- Coverage
17 analysts
- Current price
About $28
- Peptide blind spot
Most analyst models do not yet include peptide revenue. BofA says explicitly that peptides are pure upside.
- Upside to consensus
About 13%
International business
- 2025 revenue
$134 million (up about 400% year on year)
- Acquisitions
- ZAVA
- Livewell
- Eucalyptus markets
- Australia
- Japan
- UK
- Germany
- Canada
- Management target
$1 billion of international revenue within 3 years
Q1 earnings preview
- Adjusted EBITDA margin guidance
6-9%
- Date
11 May, after the close
- Reason for growth slowdown
A one-off regulatory hit to GLP-1 (a revenue headwind of about $65 million)
- Revenue guidance
$600-625 million (+2.4% to 6.7% YoY)
- Watchpoints
- Novo conversion rate
- Resilience of the non-GLP-1 businesses
- Progress at Labs
Valuation snapshot
- Implication
A return to the median implies a share price above $30. The market's repricing has only just begun.
- Current P/S ratio
About 2x
- Historical median P/S ratio
3.3x
- Weekly move
Up about 35-48% last week
A brief is a lead for our research, not a verified conclusion or advice.